LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Akcijų sąrašas・Amgen Inc

Amgen Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

326.2 -3.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

325.13

Max

336.3

Pagrindiniai rodikliai
By Trading Economics
Pajamos	486M 1.8B
Pardavimai	-1.3B 8.6B
P/E Sektoriaus vid.	22.936 51.415
Pelnas, tenkantis vienai akcijai	5.15
Dividendų pajamingumas	2.91
Pelno marža	21.107
Darbuotojai	31,500
EBITDA	-2.3B 2.7B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+8.47% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.91% 2.34%
Kitas uždarbis	2026-08-04
Kitas dividendų mokėjimo data	2026-06-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-5.4B 178B
Ankstesnė atidarymo kaina	329.23
Ankstesnė uždarymo kaina	326.2

Naujienos nuotaikos

By Acuity

32%

68%

81 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

270.44 / 276.44 Palaikymas ir pasipriešinimas

Amgen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-30 20:16; UTC

Uždarbis

Amgen Posts Higher 1Q Profit, Revenue

2026-04-06 17:09; UTC

Pagrindinės rinkos jėgos

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026-02-03 21:49; UTC

Uždarbis

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

2026-01-06 15:14; UTC

Įsigijimai, susijungimai, perėmimai

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

2025-11-19 21:55; UTC

Pagrindinės rinkos jėgos

Amgen Lung Cancer Drug Gets Full Approval From FDA

2026-04-30 20:01; UTC

Uždarbis

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

2026-04-30 20:01; UTC

Uždarbis

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

2026-04-30 20:01; UTC

Uždarbis

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

2026-04-30 20:01; UTC

Uždarbis

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

2026-04-30 20:01; UTC

Uždarbis

Amgen 1Q Adj EPS $5.15 >AMGN

2026-04-30 20:01; UTC

Uždarbis

Amgen 1Q Rev $8.62B >AMGN

2026-04-30 20:01; UTC

Uždarbis

Amgen 1Q Net $1.82B >AMGN

2026-04-30 20:01; UTC

Uždarbis

Amgen 1Q EPS $3.34 >AMGN

2026-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Why 2026 Is Biotech's Comeback Year -- Barrons.com

2026-02-04 19:56; UTC

Rinkos pokalbiai

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

2026-02-03 21:01; UTC

Uždarbis

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen 4Q Adj EPS $5.29 >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen 4Q Net $1.33B >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen 4Q Rev $9.9B >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen Sees FY Rev $37B-$38.4B >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

2026-02-03 21:01; UTC

Uždarbis

Amgen 4Q EPS $2.45 >AMGN

2026-01-28 17:47; UTC

Uždarbis

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

2026-01-06 14:01; UTC

Įsigijimai, susijungimai, perėmimai

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

2026-01-06 14:01; UTC

Įsigijimai, susijungimai, perėmimai

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

2026-01-06 14:00; UTC

Įsigijimai, susijungimai, perėmimai

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Akcijų palyginimas

Kainos pokytis

Amgen Inc Prognozė

Kainos tikslas

By TipRanks

8.47% į viršų

12 mėnesių prognozė

Vidutinis 364.7 USD 8.47%

Aukščiausias 427 USD

Žemiausias 300 USD

Remiantis 24 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Amgen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

24 ratings

Pirkti

Laikyti

Parduoti

Remiantis 24 analitikų, pateikusių Amgen Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

270.44 / 276.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

81 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.